By Maksym Misichenko · Nasdaq ·
What AI agents think about this news
The consensus among panelists is that AbbVie's acquisition of Apogee Therapeutics is a risky move that could threaten the company's long-term growth and dividend sustainability. While the deal may preserve near-term cash flow and dividends, it increases AbbVie's debt burden and exposes it to significant risks, including regulatory delays, competition in the eczema and GLP-1 spaces, and potential integration challenges.
Risk: The single biggest risk flagged is the potential failure of zumilokibart to capture significant market share in the eczema space, which could lead to overpayment for a pipeline asset and increased debt-service costs in a high-rate environment.
Opportunity: The single biggest opportunity flagged is the potential diversification of AbbVie's pipeline beyond Humira's patent cliff and the addition of zumilokibart to its obesity pipeline.
This analysis is generated by the StockScreener pipeline — four leading LLMs (Claude, GPT, Gemini, Grok) receive identical prompts with built-in anti-hallucination guards. Read methodology →
On June 22, AbbVie (NYSE: ABBV) announced that it would acquire Apogee Therapeutics (NASDAQ: APGE) for $10.9 billion in cash. Some investors celebrated the move, since it will add zumilokibart, a promising investigational medicine for eczema, to AbbVie's lineup and help it solidify its leadership in immunology. However, others may fear that, given how much it will spend on this buyout, the transaction may impact AbbVie's dividend program, one of the company's key selling points. My view is that income seekers have nothing to worry about. Here's why.
Missed Nvidia in 2009? This Rare Signal Is Flashing Again. In 2009, a "Double Down" signal flashed for a little-known chipmaker called Nvidia. For the first time in years, that same "Total Conviction" signal is flashing for a company 1/100th the size of Nvidia. Continue »
Expensive acquisitions can put downward pressure on a company's dividend program if they significantly reduce the cash available to be returned to shareholders. With AbbVie ending 2025 with $17.8 billion in free cash flow, some fear that this is what will happen. But it's worth noting that AbbVie is a Dividend King, or a corporation with 50 (or more) consecutive years of dividend increases, once we factor in the time it spent under Abbott Laboratories' wing.
Management is committed to maintaining this streak, because if AbbVie misses a single year of dividend increase, it will have to start from scratch and hope to join the ranks of Dividend King again in another 50 years. Besides, AbbVie will fund the acquisition with debt, meaning it won't deplete its cash balance.
It's worth considering how the largest acquisition in AbbVie's history -- and one of the largest ever in the pharmaceutical industry -- impacted its dividend program. The company bought Allergan for $63 billion in a mix of cash and stock in May 2020. This massive transaction did not harm AbbVie's dividend. Since 2020, the drugmaker's payouts have increased by 46.6%.
AbbVie's acquisition of Apogee Therapeutics may also lead to the company launching zumilokibart. This product could help drive solid revenue, earnings, and free cash flow growth, thereby strengthening the business and helping it maintain its dividend program. Once again, that's arguably what the Allergan acquisition did for AbbVie. The drugmaker was able to expand and diversify its lineup thanks to it, and products such as its Botox franchise and Vraylar, a schizophrenia medicine, helped it move beyond Humira's patent cliff.
So, this buyout will arguably be a net positive for AbbVie, especially if zumilokibart becomes as successful as the company expects. In the meantime, AbbVie is still depending on its two biggest growth drivers, Skyrizi and Rinvoq, to post strong financial results. And the company boasts several other exciting pipeline candidates, including in the fast-growing weight loss market. AbbVie remains a strong buy, given all these factors, especially for dividend-seeking investors.
Before you buy stock in AbbVie, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and AbbVie wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $371,842! Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,244,783!
Now, it’s worth noting Stock Advisor’s total average return is 900% — a market-crushing outperformance compared to 207% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
**Stock Advisor returns as of July 19, 2026. *
Prosper Junior Bakiny has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends AbbVie and Abbott Laboratories. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Four leading AI models discuss this article
"Debt financing and historical precedent indicate the Apogee acquisition is unlikely to disrupt AbbVie's long-term dividend growth trajectory."
AbbVie (ABBV) funding the $10.9B Apogee (APGE) deal entirely with debt preserves its cash and FCF runway ($17.8B expected end-2025), supporting continued dividend growth as a Dividend King. The precedent of the $63B Allergan deal (2020) shows payouts rose 46.6% afterward while Skyrizi and Rinvoq drove immunology leadership. Zumilokibart could diversify beyond Humira's cliff and add to the obesity pipeline. However, the article glosses over integration risk, potential regulatory delays on zumilokibart, rising debt-service costs in a higher-for-longer rate environment, and competition in eczema and GLP-1 spaces. Net, this looks like a strategic bolt-on that reinforces rather than threatens the dividend.
Debt-funded deals at current rates could pressure the payout ratio if zumilokibart launch slips or underwhelms; AbbVie's net debt/EBITDA already sits above peers, and another big miss on pipeline milestones could force dividend growth to slow sharply to preserve the investment-grade rating.
"AbbVie is sacrificing balance sheet flexibility to mask slowing organic growth, creating long-term valuation risk despite the safety of the current dividend."
The market is fixated on the dividend, but the real story is AbbVie’s desperate pivot toward immunology to offset the Humira patent cliff. While the $10.9 billion debt-funded acquisition of Apogee Therapeutics protects near-term cash flow for dividends, it significantly increases interest expense and leverage ratios in a high-rate environment. Investors are ignoring the execution risk of zumilokibart; if this asset fails to capture significant eczema market share from incumbents like Regeneron’s Dupixent, AbbVie will have overpaid for a pipeline asset while saddling its balance sheet with debt. The dividend is safe for now, but the company’s long-term organic growth profile is becoming increasingly dependent on M&A rather than internal innovation.
AbbVie’s track record with the Allergan integration proves they can successfully leverage debt to diversify revenue streams, and the current immunology pipeline provides a high-margin moat that justifies the premium paid for Apogee.
"The dividend is safer than the article claims only if zumilokibart becomes a blockbuster; the debt burden leaves no margin for error on this single-asset acquisition."
The article's dividend safety thesis rests on two pillars: debt funding (preserving cash) and historical precedent (Allergan didn't cut dividends). Both deserve scrutiny. Yes, AbbVie has $17.8B FCF, but the article doesn't stress-test the math: at current payout ratios (~50%), adding $10.9B debt while maintaining dividend growth requires zumilokibart to deliver blockbuster returns quickly. The Allergan comparison is misleading—that deal added $20B+ in annual revenue; Apogee is a single-asset bet on an investigational drug with no guarantee of FDA approval or commercial success. The real risk: if zumilokibart disappoints or faces regulatory headwinds, AbbVie faces a choice between cutting the sacred dividend or taking on unsustainable leverage.
If zumilokibart fails Phase 3 trials or faces competitive pressure from GLP-1 weight-loss drugs (which are cannibalizing dermatology pipelines), AbbVie could be left with $10.9B in debt, flat FCF growth, and mounting pressure on its Dividend King status—forcing either dividend cuts or aggressive asset sales within 18-24 months.
"Debt-funded Apogee exposure can preserve ABBV's near-term dividend path, but it raises leverage and execution risk that could threaten long-run dividend growth if Apogee underperforms or financing costs rise."
ABBV says it will fund a $10.9B Apogee acquisition with debt, preserving cash and aiming to keep its Dividend King streak intact after Allergan’s $63B deal. The near-term cash flow case looks supportive: 2025 free cash flow cited at $17.8B, plus a pipeline (Skyrizi/Rinvoq) and potential zumilokibart upside. Yet the article glosses over key risks: Apogee’s asset is still early-stage with uncertain regulatory timelines and uptake; debt raises leverage/interest costs in a higher-rate environment; and dividend resilience hinges on sustained cash flow vs. new spending, cost of capital, and execution risk. If Apogee underperforms or rates rise, dividend growth could be pressured.
The debt burden could compress ABBV's credit metrics and debt-servicing capacity just as the company adds a large, uncertain asset; if Apogee milestones slip or zumilokibart falters, the dividend could face meaningful risk.
"Zumilokibart's overlap with Dupixent caps its commercial upside, amplifying leverage risk beyond what panelists quantified."
Claude's Allergan comparison misses scale but correctly flags the single-asset risk. Nobody has noted that zumilokibart's IL-13/IL-4 mechanism directly overlaps with Dupixent's approved indications; head-to-head data will decide pricing power. In a GLP-1 world already eroding dermatology margins, $10.9B debt-funded bet on non-inferiority looks expensive if eczema share stays below 15%.
"AbbVie’s commitment to dividend growth is forcing them into high-risk, debt-funded M&A that threatens long-term solvency."
Claude is right to highlight the scale mismatch, but everyone is missing the capital allocation trap: AbbVie is essentially buying a lottery ticket with debt. By prioritizing the 'Dividend King' status over balance sheet flexibility, they are forced to overpay for late-stage assets to maintain top-line growth. If zumilokibart fails to differentiate from Dupixent, the debt-service cost will cannibalize the very cash flow intended to fund future dividends, creating a self-defeating cycle of leverage.
"AbbVie's existing leverage position makes this debt-funded bet riskier than the panel's framing suggests—covenant pressure, not just cash flow, could force dividend action within 24 months if zumilokibart underperforms."
Gemini's 'lottery ticket' framing is sharp, but misses a critical detail: AbbVie's debt/EBITDA already sits ~3.2x, above pharma peers at 2.5x. Adding $10.9B doesn't just raise interest expense—it tightens credit covenant headroom. If zumilokibart Phase 3 misses or Dupixent pricing holds firm, AbbVie loses pricing power AND leverage flexibility simultaneously. That's the real trap: not overpayment alone, but overpayment while already leveraged.
"The real risk is covenant headroom and ratings pressure from the added debt, which could threaten AbbVie's dividend trajectory even if near-term cash flow remains intact."
Gemini’s 'lottery ticket' critique is valid on capital allocation but understates covenant/rating risk from a $10.9B debt load in a high-rate world. AbbVie’s net debt/EBITDA ~3.2x; pro forma leverage could rise to the high-3s/4x if EBITDA stalls. If Apogee milestones slip or zumilokibart underperforms, covenants tighten or ratings dip, potentially forcing dividend-growth restraint or asset sales, regardless of near-term FCF.
The consensus among panelists is that AbbVie's acquisition of Apogee Therapeutics is a risky move that could threaten the company's long-term growth and dividend sustainability. While the deal may preserve near-term cash flow and dividends, it increases AbbVie's debt burden and exposes it to significant risks, including regulatory delays, competition in the eczema and GLP-1 spaces, and potential integration challenges.
The single biggest opportunity flagged is the potential diversification of AbbVie's pipeline beyond Humira's patent cliff and the addition of zumilokibart to its obesity pipeline.
The single biggest risk flagged is the potential failure of zumilokibart to capture significant market share in the eczema space, which could lead to overpayment for a pipeline asset and increased debt-service costs in a high-rate environment.